MULTILOCATION TRIALS OF KOIHERPES VIRUS VACCINE FOR KOIHERPES VIRUS DISEASE PREVENTION IN KOI Cyprinus carpio koi

Lila Gardenia*, Tuti Sumiati, and Nunak Nafiqoh
 
Research Institute for Freshwater Aquaculture
Jl. Sempur No. 1 Bogor - West Java, INDONESIA
lila.abimanyu@gmail.com  

Koiherpes virus disease (KHVD) has caused huge losses to the aquaculture industry expecially on koi and common carp. KHV outbreaks in koi and common carp causes  high mortality and currently there's no effective drugs to prevent and treat the infected fish.Vaccination is the only method to prevent the disease and it's used to induce fish immunity. Commercial KHV vaccine from Israel which available in Indonesia is an attenuated vaccine, which has some potential to become active, back into wild type or mutate into a new strain that could be more virulent. Therefore, many people who suggested the use of inactivated viruses which have a smaller risk than attenuate done. This study was aimed to test the efficacy of Koiherpes virus vaccine in several location of fish farming to prevent koiherpes virus infection in koi.

In this research, Koiherpes virus was propagated in cell culture and then inactivated by 0.1% formalin at concentration of 106.45 TCID50 virus/mL. In this research, multi location trials were done in two locations: Ciherang (Cianjur-West Java) and Ciseeng (Bogor-West Java) for a period of 12 weeks with 3 group in duplicated (vaccinated fish with single application by immersion; vaccinated fish with booster by immersion on the 6th weeks after priming; and non-vaccinated fish as control.

Survival rate in Ciherang after 12 weeks in each group: 86.6%, 82.2% and 85.6% and in Ciseeng 75%, 71.3% and 60%. Challenge test by of cohabitation with infected fish. Cumulative mortality showed that vaccine application provide quite high protection for koi as lower number of fish died in vaccinated group than control.